Objectives: To investigate the efficacy of cidofovir to block gammaherpesvirus replication in the context of sexual transmission.
Introduction
Gammaherpesviruses (cHVs) are important pathogens that are ubiquitous in both human and animal populations. Thus, EpsteinBarr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) infect, respectively, up to 90% and 30% of humans worldwide and are associated with several human malignancies such as Burkitt's and Hodgkin's lymphomas, nasopharyngeal carcinoma, Kaposi's sarcoma and post-transplant lymphoproliferative disease. [1] [2] [3] Efficient control of these infections is therefore of major interest, particularly in immunocompromised people. 4 The very high infection prevalence of these infections is due to efficient transmission from carriers to new hosts 5 and reflects the fact that these viruses have evolved to coexist with immune responses. Indeed, cHVs establish persistent, productive infections, with virus carriers both making antiviral immune responses that protect against disease and excreting infectious virions. While interrupting transmission is the sine qua non of infection control, strategies based on vaccination have therefore been mainly unsuccessful to reach this goal. For example, vaccination with the EBV gp350, to block virion binding to B cells, failed to reduce infection rates while protecting against infectious mononucleosis. 6, 7 Other approaches to block transmission are therefore needed.
Antiviral drugs are another way to fight viral infections. 8 No antiviral drugs are currently licensed for treatment of KSHV or EBV infections. However, several antiherpesvirus drugs have been shown to block these infections in vitro, especially those targeting the viral DNA polymerase or viral DNA replication, such as aciclovir, ganciclovir, foscarnet and cidofovir. [8] [9] [10] [11] [12] Cidofovir, also called HPMPC {for (S)-1-[3-hydroxy-2-(phosphomethoxy)propyl]cytosine}, is a nucleotide analogue that needs to be phosphorylated by cellular kinases to its diphosphate form to become biologically active and block viral DNA polymerase. 13 When evaluated in an in vivo model, cidofovir proved to be very efficacious in protecting mice from cHV-induced disease whereas aciclovir, ganciclovir and foscarnet had little or no effect. While cidofovir and related molecules are promising compounds for future clinical development to fight cHV infection, their use in the context of viral transmission has never been investigated.
Analysing EBV and KSHV transmission has proved difficult as these viruses have no well-established in vivo infection models. Related animal viruses, such as murid herpesvirus 4 (MuHV-4), provide another way to address such questions.
14 Indeed, using luciferase imaging of MuHV-4 infection, 15 we recently observed genital MuHV-4 excretion following intranasal inoculation of female mice and transmission to naive males after sexual contact. 16 Interestingly, that way of transmission also occurs for the KSHV transmission associated with HIV infection 17 and may also apply to EBV. 18 In this study, we therefore want to investigate whether cidofovir could block cHV replication in conditions of sexual transmission close to natural settings.
Materials and methods

Ethics statement and animals
Experiments, maintenance and care of mice complied with the guidelines of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes. The Committee on the Ethics of Animal Experiments of the University of Liège, Belgium approved the protocol (Permit Number: 1502). All efforts were made to limit animal suffering. BALB/c mice were purchased from ENVIGO Laboratories and were housed under conventional conditions in the Department of Infectious Diseases, University of Liège, Liège, Belgium. Female mice were used at the age of 8 weeks and their weight was 20+1.5 g. Mice were infected intranasally with 10 4 pfu of MuHV-4 diluted in 30 lL of sterile PBS, under general anaesthesia with isoflurane. Animals were randomly allocated to experimental groups.
Antiviral compound
Mice were injected subcutaneously at different timepoints according to experimental design with 25 mg/kg/day cidofovir (Gilead Sciences) diluted in PBS.
Viral strain
All viruses were derived from a MuHV-4 bacterial artificial chromosome (BAC). 19 We used a strain expressing luciferase under the control of the M3 promoter that has been described previously (WT Luc! strain). 15 The loxPflanked BAC/eGFP cassette was removed by subsequent growths of the virus in NIH-3T3-CRE cells until eGFP! cells were no longer visible. 20 Virus stocks were grown in BHK-21 cells cultured in DMEM (Gibco) supplemented with 2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin and 10% FCS. Cell culture medium was cleared of cell debris by low-speed centrifugation (1000 g, 30 min). Viruses were then concentrated by high-speed centrifugation (100 000 g, 90 min) and titrated by plaque assay on BHK-21 cells as described elsewhere. 21 
In vivo imaging
Mice were anaesthetized, injected intraperitoneally with luciferin (60 mg/kg) and imaged 10 min later with an IVIS Spectrum (Perkin Elmer). Quantification of anti-MuHV-4-specific antibodies by ELISA MuHV-4 virions pelleted as described above were disrupted by addition to the viral preparation of Triton X-100 to a concentration of 0.1% (v/v). Nunc Maxisorp ELISA plates (Nalgene Nunc) were coated for 18 h at 4 C with Triton X-100-disrupted MuHV-4 virions (10 6 pfu equivalents/well), blocked in PBS/0.1% Tween 20/3% BSA, and incubated with mouse sera (diluted 1/200 in PBS/0.1% Tween 20) . Bound antibodies were detected with alkalinephosphatase-conjugated goat anti-mouse immunoglobulin (Ig) polyclonal antibody (Sigma-Aldrich). Washing was performed with PBS/0.1% Tween 20. p-Nitrophenylphosphate (Sigma-Aldrich) was used as substrate for colorimetry and absorbance was read at 405 nm using a Benchmark ELISA plate reader (Thermo). Sera were considered as positive when absorbance was superior to the mean value of mock-infected mice ! 3 standard deviations (represented by a broken line in the figures).
Viral genome quantification
MuHV-4 genomic coordinates 40 264-44 385 were amplified as described (ORF25 gene, forward primer 5 0 -ATGGTATAGCCGCCTTTGTG-3 0 , reverse primer 5 0 -ACAAGTGGATGAAGGGTTGC-3 0 ). 22 The PCR products were quantified by hybridization with a TaqMan probe (genomic coordinates 43 088-43 117, 5 0 6-FAM-TTCATAAGTTTTATGCTGATCCAGTGGTTG-BHQ1 3 0 ) and converted to genome copies by comparison with a standard curve of cloned plasmid template serially diluted in control mouse spleen DNA and amplified in parallel (iCycler, Bio-Rad). Cellular DNA was quantified by amplifying part of the mouse interstitial retinoid binding protein (IRBP) gene (forward primer 5 0 -ATCCCTATGTCATCTCCTACYTG-3 0 , reverse primer 5 0 -CCRCTGCCTTCCCATGTYTG-3 0 ). The PCR products were quantified with Sybr green (Invitrogen), the copy number was calculated by comparison with a standard curve of cloned mouse IRBP template amplified in parallel. Amplified products were distinguished from paired primers by melting curve analysis and the correct sizes of the products confirmed by electrophoresis and staining with ethidium bromide.
Statistical analyses
Fisher's exact test or unpaired, two-sided Student's t-test was used for comparisons between two sets of data. If multiple groups of data were compared simultaneously, an ANOVA was used and Bonferroni post-tests were used to compare groups. A P value ,0.05 was used for statistical significance.
Results
Daily cidofovir treatment of infected females leads to reduction of MuHV-4 genital excretion
In order to test the effect of cidofovir treatment on MuHV-4 transmission, we firstly investigated if cidofovir could reduce MuHV-4 genital excretion from infected female mice. We infected 8-week-old BALB/c female mice with a MuHV-4 strain expressing luciferase under the control of the M3 lytic promoter (WT Luc strain). 15 Indeed, using this strain, we previously showed that, following intranasal infection, a luciferase signal is observed in the genital tract of 80% of infected female mice, that this signal is associated with viral excretion and that this Zeippen et al.
excretion occurs in most of the cases between days 17 and 21 post-infection. 16 Moreover, we showed that excretion of infectious virus in the female genital tract allows sexual transmission to naive males ( Figure S1 , available as Supplementary data at JAC Online). 16 Therefore, cidofovir was given on a daily basis from day 15 post-infection until day 22 post-infection (n " 20) (Figure 1a 
A single cidofovir treatment of infected females does not reduce MuHV-4 genital excretion
Daily cidofovir treatment is usually used in mice. 12 However, in humans a weekly administration is sufficient and allows the reduction of associated adverse effects. Therefore, in order to address the effect of a single cidofovir treatment, we repeated the same experiment by replacing the daily injections by a single injection of cidofovir performed at day 14 post-infection as genital excretion usually starts from day 17 ( Figure 2a) . 16 Once-daily cidofovir treatment of naive males prevents MuHV-4 replication and latency establishment While antiviral treatments could be used to reduce excretion and transmission from infected subjects, they could also prevent replication in naive ones. We therefore investigated the potency of a daily cidofovir treatment to block MuHV-4 replication and host colonization in naive males after sexual contact with excreting females. Briefly, we infected female BALB/c mice with the MuHV-4 WT Luc! strain and followed them by in vivo imaging in order to detect MuHV-4 genital excretion. When the genital signal was observed (between days 17 and 21 depending on the females), excreting females were mated with naive males, treated or not with cidofovir from days 15 to 24 (day 0 was defined as the time of female intranasal infection). At day 24, males were separated from females and were followed by in vivo imaging to monitor viral replication (Figure 3a-c) . Strikingly, no males displayed the genital signal after daily treatment with cidofovir (n " 0/15) while a transmission rate of 35% was observed in the control group (Figure 3b and c). Males of both groups were euthanized at day 41. In contrast with males from the PBS-treated group, none of the males from the cidofovir-treated group displayed seroconversion to MuHV-4 infection (Figure 3d ) or latency establishment in the spleen (Figure 3e) . Altogether, these results show that once-daily cidofovir administration to naive males (started 2 days before putting males in contact with genitally excreting females and maintained for the whole contact period with infected females) is sufficient to prevent replication and host colonization following sexual contact with MuHV-4-excreting females.
A single preventive cidofovir treatment of naive males 2 to 6 days before sexual contact is not sufficient to prevent MuHV-4 sexual infection
We then used a single preventive injection of cidofovir to naive males in order to test if it was sufficient to prevent viral replication and host colonization. Briefly, we repeated the same experimental design as described above except that males received a single injection of cidofovir at day 15 (day 0 was defined as the time of female intranasal infection) (Figure 4a) . In vivo imaging did not highlight any significant difference between cidofovir-and PBStreated groups (Figure 4b and c) . Accordingly, similar rates of seroconversion (Figure 4d ) or of latency establishment in the spleen (Figure 4e ) were observed in both groups. Altogether, these results show that a single cidofovir administration to naive males 2 to 6 days before sexual contact with females excreting the virus in the genital tract is not sufficient to prevent viral replication and latency establishment in males.
Influence of a single post-exposure cidofovir treatment of naive males on their infection through the sexual route Finally, we tested if a single post-exposure treatment of exposed naive males could be sufficient to block systemic infection and latency establishment. Briefly, we repeated the same experimental scheme as the one described above, but instead of treating naive males 2 to 6 days before sexual contact with MuHV-4-excreting females, males received a single injection of cidofovir 24 h after contact with infected females (Figure 5a ). Interestingly, only 1 of 32 (3%) treated males displayed an MuHV-4-associated genital signal, whereas 6 of 23 (26%) became infected in the control Blockage of MuHV-4 transmission with cidofovir JAC group (Figure 5b and c) . Accordingly, seroconversion to MuHV-4 ( Figure 5d ) was also reduced in the cidofovir-treated group in comparison with the PBS-treated group. Although latency establishment (Figure 5e ) tended also to be reduced in the cidofovirtreated group this was, however, not statistically different from the PBS-treated group (P " 0.056 by Fisher's exact test). Altogether, these results suggest that, following sexual contact with MuHV-4-excreting females, a single post-exposure cidofovir administration to naive males reduces MuHV-4 replication and seroconversion against the virus.
Discussion
cHVs are highly prevalent animal and human viruses that are associated with numerous pathological conditions. In immunocompromised people, EBV and KSHV cause cancers and other disorders such as Burkitt's lymphoma, Kaposi's sarcoma or Castleman disease. 4, 23 Moreover, primary infection of young adults with EBV causes infectious mononucleosis, which represents major health costs. 24 EBV-induced infectious mononucleosis also increases the risk of developing multiple sclerosis to a similar degree as the strongest genetic risk factor. 25 Preventing cHV infection in some defined populations is therefore a major public health challenge. Over the last 50 years, several antivirals have been developed to treat different infectious conditions. 8 In the case of herpesviruses, viral DNA polymerase is a key target for the development of potent inhibitors. Thus, acyclic nucleoside phosphonates, such as cidofovir, are important broad-spectrum antiviral agents, which emerged as the most potent anti-cHV drugs. 13 In this study, we tested the capacity of cidofovir to block cHV replication and host colonization in the context of sexual transmission. (d) Anti-MuHV-4 serology in males at euthanasia (n " 15 mice per group, except the mock-infected group, which was made of 5 mice). The broken line represents the mean value of mock-infected mice ! 3 standard deviations. (e) Viral genomes per spleen cell of males at euthanasia (n " 15 mice per group, except the mock-infected group, which was made of 3 mice). Avg, average; CDV, cidofovir; d, day; in, intranasal; ns, not significant.
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Briefly, we showed that once-daily treatment of either infected females or naive males is sufficient to significantly reduce viral excretion from infected females and viral replication and latency establishment in naive males (Figures 1 and 3) . In particular, treatment of the uninfected males not only reduced initial viral replication in the male penis to levels undetectable by the IVIS system but also protected these mice from seroconversion to MuHV-4 and from latency establishment in the spleen (Figure 3 ). In contrast, cidofovir treatment of excreting females did not affect the levels of virus latency in the spleen but was sufficient to reduce virus excretion anyway (Figure 1 ). This approach could potentially be translated to human viruses as MuHV-4, EBV and KSHV display similar sensitivity to cidofovir even if measures of EC 50 have not been performed in the same conditions. 13 Moreover, a similar approach had already been shown to be successful in the case of sexual transmission of herpes simplex virus 2 (HSV-2) in human where once-daily valaciclovir treatment of the infected partner reduced the risk of HSV-2 transmission between heterosexual, monogamous couples discordant for HSV-2 infection. 26, 27 Such an approach could also apply to animals in specific conditions. For example, some cHVs, such as those associated with malignant catarrhal fever, cause recurrent problems in zoos where persistently infected and susceptible animals are housed in close contact. 28, 29 As these viruses are frequently transmitted upon parturition, treatment of persistently infected mothers around these periods could likely reduce virus excretion Blockage of MuHV-4 transmission with cidofovir JAC and help to protect neighbouring susceptible species. Of course, the sensitivity of these viruses to cidofovir will have to be determined.
One of the major pitfalls of nucleoside analogues resides in their toxicity in the long term. We therefore tested the capacity of a single cidofovir injection (either to the infected or to the naive partner) before sexual contact to block MuHV-4 transmission (Figures 2 and 4) . Neither of these two approaches were revealed as successful at the end of the experimental protocol while a reduction in genital excretion was observed until day 19 (P , 0.05 by v 2 test) in infected females treated with cidofovir ( Figure 2) . Therefore, although preventive cidofovir treatment has the potential to efficiently block cHV transmission, the establishment of protocols based on a single injection will be difficult and is likely directly linked with the in vivo t1 =2 of the drug. Cidofovir has a long intracellular t1 =2 of about 15 to 65 h and a single administration of 30 mg/kg (similar to the 25 mg/kg used in our protocols) protects mice from poxvirus infections 3 days later but not 5 days later. 30 Similarly, we observed that a single cidofovir injection is sufficient to block excretion of MuHV-4 from infected females for 5 days (Figure 2 ; between days 14 and 19 post-infection). A single administration to naive males also delayed their infection (Figure 4) . Therefore, usage of cidofovir as a preventive treatment to block sexual transmission of cHV will require a frequency of administration that allows maintenance of efficient concentration of the drug and its metabolites in cells but does not induce side effects such as nephrotoxicity. Alternatively, these objectives could be reached by the use of brincidofovir, a novel oral lipid-conjugated nucleotide analogue, which is converted into cidofovir in the target cells and has shown enhanced in vitro activity against some herpesviruses while displaying reduced toxicity in vivo.
31
While preventive pre-exposure administration of antivirals is difficult to implement to block transmission, post-exposure treatment could display obvious advantages. Interestingly, we showed here that a single cidofovir administration to males 24 h postsexual contact with MuHV-4-excreting females significantly reduced virus replication in the male genital area and seroconversion at euthanasia suggesting that a single cidofovir treatment could be efficient ( Figure 5 ). However, reduction of viral genome copy numbers in the spleens was not statistically significant ( Figure 5e ) suggesting a reduced replication at the entry site but host colonization anyway.
The feasibility of such an approach in the field could depend on the major mode of transmission of cHVs in those conditions. Endemic EBV and KSHV infections are maintained chiefly by carriers shedding virus into their saliva. In that context, single postexposure administration is likely not feasible. However, numerous reports have shown that cHVs could be sexually transmitted in some circumstances. 32 This was seen clearly for the KSHV transmission associated with HIV infection 17 and may apply also to EBV. 18, 33 In such a context, post-exposure treatment could probably be an option.
Altogether, we have shown that cidofovir could be used to efficiently block transmission of a cHV in conditions close to what happens in real life. Especially, it appeared that post-exposure treatment could be a very interesting approach in some epidemiological conditions regarding its efficacy and its ease of implementation.
